STAT5A and acute myeloid leukemia: Preclinical studies established that quizartinib achieves plasma concentrations sufficient to inhibit phospho-FLT3 in both FLT3-ITD–mutated and FLT3–wild-type AML cells, while also inhibiting phospho-STAT5 downstream signaling [66].